Trials / Terminated
TerminatedNCT00430716
To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sildenafil citrate | oral, 20 mg, tid |
| DRUG | Sildenafil citrate | oral 1 mg, tid |
| DRUG | Sildenafil citrate | oral 5 mg, tid |
| DRUG | Sildenafil citrate | oral 20 mg, tid |
Timeline
- Start date
- 2008-04-08
- Primary completion
- 2010-05-25
- Completion
- 2010-05-25
- First posted
- 2007-02-02
- Last updated
- 2020-12-22
- Results posted
- 2011-05-17
Locations
46 sites across 17 countries: United States, Belgium, Brazil, Bulgaria, China, Greece, India, Italy, Latvia, Malaysia, Netherlands, Philippines, Poland, Romania, Russia, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00430716. Inclusion in this directory is not an endorsement.